AstraZeneca PLC AZN.OQ, AZN.O is expected to show a rise in quarterly revenue when it reports results on February 6 for the period ending December 31 2024
The Cambridge United Kingdom-based company is expected to report a 18.9% increase in revenue to $14.292 billion from $12.02 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for AstraZeneca PLC is for earnings of $1.03 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for AstraZeneca PLC is $88.00, above its last closing price of $69.86.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 1.01 | 1.03 | 1.04 | Beat | 1 |
Jun. 30 2024 | 1.17 | 1.00 | 0.99 | Missed | -1 |
Mar. 31 2024 | 1.20 | 1.22 | 1.03 | Missed | -15.8 |
Dec. 31 2023 | 0.76 | 0.79 | 0.73 | Missed | -7.8 |
Sep. 30 2023 | 0.84 | 0.85 | 0.87 | Beat | 3 |
Jun. 30 2023 | 1.01 | 0.95 | 1.08 | Beat | 13.7 |
Mar. 31 2023 | 1.13 | 1.07 | 0.96 | Missed | -10.3 |
Dec. 31 2022 | 0.67 | 0.67 | 0.69 | Beat | 3 |
This summary was machine generated February 4 at 07:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。